DK1764361T3 - Krystal af 1,2-dihydropyridinforbindelse og fremgangsmåde til fremstilling heraf - Google Patents

Krystal af 1,2-dihydropyridinforbindelse og fremgangsmåde til fremstilling heraf

Info

Publication number
DK1764361T3
DK1764361T3 DK05758232.2T DK05758232T DK1764361T3 DK 1764361 T3 DK1764361 T3 DK 1764361T3 DK 05758232 T DK05758232 T DK 05758232T DK 1764361 T3 DK1764361 T3 DK 1764361T3
Authority
DK
Denmark
Prior art keywords
crystal
preparation
dihydropyridine compound
dihydropyridine
compound
Prior art date
Application number
DK05758232.2T
Other languages
English (en)
Inventor
Itaru Arimoto
Satoshi Nagato
Yukiko Sugaya
Yoshio Urawa
Koichi Ito
Hiroyuki Naka
Takao Omae
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35782900&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1764361(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Application granted granted Critical
Publication of DK1764361T3 publication Critical patent/DK1764361T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/64One oxygen atom attached in position 2 or 6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK05758232.2T 2004-07-06 2005-07-05 Krystal af 1,2-dihydropyridinforbindelse og fremgangsmåde til fremstilling heraf DK1764361T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004198709 2004-07-06
PCT/JP2005/012388 WO2006004107A1 (ja) 2004-07-06 2005-07-05 1,2-ジヒドロピリジン化合物の結晶およびその製造方法

Publications (1)

Publication Number Publication Date
DK1764361T3 true DK1764361T3 (da) 2013-05-06

Family

ID=35782900

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05758232.2T DK1764361T3 (da) 2004-07-06 2005-07-05 Krystal af 1,2-dihydropyridinforbindelse og fremgangsmåde til fremstilling heraf

Country Status (29)

Country Link
US (3) US8304548B2 (da)
EP (3) EP2586771A3 (da)
JP (3) JPWO2006004107A1 (da)
KR (2) KR101187218B1 (da)
CN (7) CN1984890A (da)
AT (1) ATE547405T1 (da)
AU (2) AU2005258385B2 (da)
BR (1) BRPI0510254B8 (da)
CA (2) CA2570177C (da)
CY (1) CY1114313T1 (da)
DK (1) DK1764361T3 (da)
ES (1) ES2404697T3 (da)
HK (2) HK1102127A1 (da)
HR (1) HRP20130363T1 (da)
IL (2) IL180024A (da)
JO (1) JO2832B1 (da)
ME (1) ME01520B (da)
MX (1) MXPA06014458A (da)
MY (1) MY148809A (da)
NO (1) NO339101B1 (da)
NZ (1) NZ550720A (da)
PL (2) PL1764361T3 (da)
PT (1) PT1764361E (da)
RS (1) RS52752B (da)
RU (1) RU2323930C1 (da)
SI (2) SI1772450T1 (da)
TW (1) TW200606144A (da)
WO (2) WO2006004107A1 (da)
ZA (1) ZA200609274B (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4614884B2 (ja) 2003-11-14 2011-01-19 シャンハイ ゲノミックス インク ピリドンの誘導体とその使用
AU2006232517A1 (en) * 2005-04-04 2006-10-12 Eisai R&D Management Co., Ltd. Dihydropyridine compounds and compositions for headaches
PL1928454T3 (pl) 2005-05-10 2015-03-31 Intermune Inc Pochodne pirydonu do modulowania układu kinazy białkowej aktywowanego stresem
US20090088574A1 (en) * 2005-12-21 2009-04-02 Eisai R&D Management Co., Ltd. Crystal of 1,2-dihydropyridine compound (type iv)
CA2634056C (en) 2005-12-21 2014-06-10 Eisai R&D Management Co., Ltd. Amorphous form of 1,2-dihydropyridine compound
US7718807B2 (en) 2006-04-28 2010-05-18 Eisai R&D Management Co., Ltd. Salt of 1,2-dihydropyridine compound
WO2007144006A1 (en) 2006-06-16 2007-12-21 H. Lundbeck A/S Crystalline forms of 4- [2- (4-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
WO2008111590A2 (en) * 2007-03-05 2008-09-18 Eisai R & D Management Co., Ltd. Ampa and nmda receptor antagonists for neurodegenerative diseases
EP2132155A4 (en) * 2007-03-29 2010-05-05 Agency Science Tech & Res PROCESS FOR PRODUCING OPTICALLY ACTIVE CYANOHYDRIN DERIVATIVE
US20100130537A1 (en) * 2007-04-26 2010-05-27 Eisai R&D Management Co., Ltd Cinnamide compounds for dementia
CA2690086A1 (en) * 2007-07-13 2009-01-22 Masanori Tsuno Ampa receptor antagonists and aldose reductase inhibitors for neuropathic pain
JP2010533126A (ja) * 2007-07-13 2010-10-21 エーザイ・アール・アンド・ディー・マネジメント株式会社 神経因性疼痛の治療ためのampa受容体アンタゴニストとアセチルコリンエステラーゼ阻害剤との併用
US20100179193A1 (en) * 2007-07-13 2010-07-15 Eisai R&D Management Co., Ltd AMPA Receptor Antagonists and Zonisamide for Neuropathic Pain
WO2009054544A1 (en) * 2007-10-26 2009-04-30 Eisai R & D Management Co., Ltd. Ampa receptor antagonists for parkinson's disease and movement disorders
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
CA2986195A1 (en) * 2009-03-25 2010-09-30 Abbvie Inc. Substituted aryl antivrial compounds and uses thereof
ITMI20111952A1 (it) 2011-10-27 2013-04-28 Italiana Sint Spa Procedimento per la prepazione di 2-metossi-5-(piridin-2-il)piridina, un intermedio del perampanel
WO2013102897A1 (en) * 2012-01-03 2013-07-11 Mapi Pharma Ltd. Polymorphs of perampanel
ITMI20121390A1 (it) 2012-08-06 2014-02-07 F I S Fabbrica Italiana Sint P A Procedimento per la preparazione di acido 2-cianofenilboronico e suoi esteri, intermedi del perampanel o di e2040
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
US9695147B2 (en) 2013-07-25 2017-07-04 Teva Pharmaceuticals International Gmbh Process for the preparation of perampanel
CN104649962A (zh) * 2013-11-25 2015-05-27 天津市汉康医药生物技术有限公司 吡仑帕奈倍半水合物化合物
CN103664756A (zh) * 2013-11-26 2014-03-26 苏州晶云药物科技有限公司 吡仑帕奈新晶型a及其制备方法
CN104706604A (zh) * 2013-12-12 2015-06-17 北京星昊医药股份有限公司 一种吡仑帕奈冻干口崩片及其制备方法
MX2016012808A (es) 2014-04-02 2017-01-05 Intermune Inc Piridinonas anti-fibroticas.
CN105085382B (zh) * 2014-05-14 2019-10-18 江苏豪森药业集团有限公司 吡仑帕奈异构体晶型及其制备方法和用途
CN103980188B (zh) * 2014-05-30 2016-01-27 浙江永宁药业股份有限公司 一种吡仑帕奈的合成方法及其中间体和中间体的合成方法
WO2016132343A1 (en) 2015-02-17 2016-08-25 Mapi Pharma Ltd. Process and intermediates for the preparation of perampanel
WO2016147104A1 (en) * 2015-03-14 2016-09-22 Intas Pharmaceuticals Ltd. Novel process for the preparation of perampanel and its intermediates thereof
WO2016172333A1 (en) * 2015-04-21 2016-10-27 Teva Pharmaceuticals International Gmbh A solid state form of perampanel
CN105287411A (zh) * 2015-09-22 2016-02-03 美吉斯制药(厦门)有限公司 一种吡仑帕奈分散片及其制备方法
CN105906557A (zh) * 2016-03-30 2016-08-31 北京万全德众医药生物技术有限公司 2-甲氧基-5-(吡啶-2-基)吡啶的一种合成方法
CN106389367B (zh) * 2016-11-16 2020-12-18 杭州朱养心药业有限公司 吡仑帕奈包衣片剂药物组合物
CN110028442B (zh) * 2018-01-11 2020-07-17 新发药业有限公司 一种吡仑帕奈的简便制备方法
KR20200132858A (ko) 2018-03-20 2020-11-25 에자이 알앤드디 매니지먼트 가부시키가이샤 간질 치료제
EP3560934A1 (en) 2018-04-26 2019-10-30 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of pure 2-cyanophenylboronic acid and esters thereof, intermediates of perampanel or of e2040
AU2019395288A1 (en) 2018-12-14 2021-09-23 Eisai R&D Management Co., Ltd. Aqueous based pharmaceutical formulations of 1,2-dihydropyridine compounds
KR102392825B1 (ko) 2020-02-18 2022-04-29 명인제약주식회사 2-(2-옥소-1-페닐-5-피리딘-2-일피리딘-3-일)벤조니트릴과 l-말릭산의 공결정 화합물 및 이의 제조 방법
WO2021240540A1 (en) 2020-05-26 2021-12-02 Celagenex Research (India) Pvt. Ltd. Novel synergistic nutritional compositions for treating seizures and chronic inflammatory diseases
GR1010285B (el) * 2021-05-31 2022-08-24 Elpen Αε Φαρμακευτικη Βιομηχανια, Στερεες φαρμακοτεχνικες μορφες περαμπανελης

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5283761A (en) 1976-01-01 1977-07-12 Yamanouchi Pharmaceut Co Ltd Novel pyridone derivative
JPS5531072A (en) 1979-07-30 1980-03-05 Rikagaku Kenkyusho Preparation of 2-pyridone compound
IL109397A0 (en) 1993-04-28 1994-07-31 Schering Ag Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
HU219777B (hu) 1993-07-02 2001-07-30 Gyógyszerkutató Intézet Kft. Optikailag aktív 1-(4-nitro-fenil)-4-metil-7,8-metiléndioxi-3,4-dihidro-5H-2,3-benzodiazepin és eljárás előállítására
HU223945B1 (hu) 1994-09-27 2005-03-29 Yamanouchi Pharmaceutical Co., Ltd. 1,2,3,4-Tetrahidro-kinoxalin-dion-származékok és ezeket tartalmazó gyógyszerkészítmények
WO1996033974A1 (fr) 1995-04-27 1996-10-31 The Green Cross Corporation Composes heterocycliques amides et leur utilisation medicinale
WO1997018163A1 (en) 1995-11-15 1997-05-22 California Institute Of Technology Synthesis of zeolites by hydrothermal reaction of zeolite p1
DE19604920A1 (de) 1996-02-01 1997-08-07 Schering Ag Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel
US5891871A (en) 1996-03-21 1999-04-06 Cocensys, Inc. Substituted 2,3-benzodiazepin-4-ones and the use thereof
HU9600871D0 (en) 1996-04-04 1996-05-28 Gyogyszerkutato Intezet New 2,3-benzodiazepine derivatives
US6303615B1 (en) 1996-05-15 2001-10-16 Pfizer Inc 2,3 disubstituded-4(3H)-quinazolinones
DE19643037A1 (de) 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
PT968194E (pt) 1997-02-28 2004-08-31 Pfizer Prod Inc Atropisomeros de 3-aril-4(3h)-quinazolinonas e sua utilizacao como antagonistas dos receptores ampa
GB9708945D0 (en) 1997-05-01 1997-06-25 Merck Sharp & Dohme Therapeutic agents
GB9711753D0 (en) 1997-06-06 1997-08-06 Merck Sharp & Dohme Therapeutic agents
WO1999031062A1 (fr) 1997-12-17 1999-06-24 Shionogi & Co., Ltd. Nouveaux composes de pyridine
JP2002519373A (ja) 1998-07-02 2002-07-02 エーザイ株式会社 製薬組成物及びそれらの使用
DE19835918A1 (de) 1998-08-07 2000-02-10 Dresden Arzneimittel Neue antikonvulsiv wirkende 4-Amino-1-aryl-pyridin-2-one und Verfahren zu deren Herstellung
CA2412172C (en) * 2000-06-12 2012-07-24 Eisai Co., Ltd. 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
JP4208512B2 (ja) 2002-07-23 2009-01-14 株式会社クラレ 5−(2’−ピリジル)−2−ピリドン誘導体の製造方法

Also Published As

Publication number Publication date
JP2012021029A (ja) 2012-02-02
MY148809A (en) 2013-05-31
TWI346660B (da) 2011-08-11
AU2005258378B2 (en) 2011-04-28
NO20065754L (no) 2007-04-04
BRPI0510254A (pt) 2007-10-23
KR20070028459A (ko) 2007-03-12
IL180024A0 (en) 2007-05-15
PT1764361E (pt) 2013-04-23
CN104402808A (zh) 2015-03-11
JP5419944B2 (ja) 2014-02-19
ZA200609274B (en) 2008-06-25
CA2561829C (en) 2009-11-24
CN1942443A (zh) 2007-04-04
AU2005258385B2 (en) 2009-11-05
WO2006004100A8 (ja) 2006-02-23
US8304548B2 (en) 2012-11-06
CN104402807A (zh) 2015-03-11
IL180151A (en) 2012-01-31
AU2005258385A1 (en) 2006-01-12
KR100939743B1 (ko) 2010-02-04
CN101914057B (zh) 2012-07-04
CN102382047B (zh) 2014-04-23
TW200606144A (en) 2006-02-16
US20140142315A1 (en) 2014-05-22
ME01520B (me) 2014-04-20
EP2586771A2 (en) 2013-05-01
CA2570177A1 (en) 2006-01-12
JPWO2006004107A1 (ja) 2008-04-24
US8772497B2 (en) 2014-07-08
EP1764361A4 (en) 2012-05-30
BRPI0510254B8 (pt) 2021-05-25
US20100324297A1 (en) 2010-12-23
NZ550720A (en) 2009-10-30
ES2404697T3 (es) 2013-05-28
HK1102127A1 (da) 2007-11-09
EP1772450A4 (en) 2009-06-10
JO2832B1 (en) 2014-09-15
WO2006004107A1 (ja) 2006-01-12
NO339101B1 (no) 2016-11-14
KR20070008617A (ko) 2007-01-17
CN1984890A (zh) 2007-06-20
CA2570177C (en) 2012-11-20
CA2561829A1 (en) 2006-01-12
EP1772450A1 (en) 2007-04-11
HK1104999A1 (da) 2008-02-01
ATE547405T1 (de) 2012-03-15
US9045426B2 (en) 2015-06-02
RS52752B (en) 2013-08-30
EP2586771A3 (en) 2013-07-31
EP1764361B1 (en) 2013-01-30
HRP20130363T1 (en) 2013-05-31
IL180151A0 (en) 2007-06-03
WO2006004100A1 (ja) 2006-01-12
RU2323930C1 (ru) 2008-05-10
MXPA06014458A (es) 2007-03-01
AU2005258378A1 (en) 2006-01-12
JP5030206B2 (ja) 2012-09-19
KR101187218B1 (ko) 2012-10-02
JPWO2006004100A1 (ja) 2008-04-24
EP1772450B1 (en) 2012-02-29
CN101544599A (zh) 2009-09-30
SI1772450T1 (sl) 2012-06-29
EP1764361A1 (en) 2007-03-21
US20070142640A1 (en) 2007-06-21
IL180024A (en) 2011-09-27
PL1764361T3 (pl) 2013-06-28
PL1772450T3 (pl) 2012-07-31
CN101914057A (zh) 2010-12-15
CN102382047A (zh) 2012-03-21
CN1942443B (zh) 2012-05-09
SI1764361T1 (sl) 2013-07-31
CN101544599B (zh) 2012-06-06
CY1114313T1 (el) 2016-08-31
BRPI0510254B1 (pt) 2019-10-29

Similar Documents

Publication Publication Date Title
DK1764361T3 (da) Krystal af 1,2-dihydropyridinforbindelse og fremgangsmåde til fremstilling heraf
EP2364971A3 (en) 2,5-Disubstituted pyridines for the preparation of 2-substituted 5-(1-alkylthio)-alkylpyridines
DK2090575T3 (da) Fremgangsmåder og mellemprodukter til fremstillingen af N4 phenylquinazolin-4-aminderivater
NO20063576L (no) 1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes
EA200701358A1 (ru) Кристаллические формы гидрохлорида (r)-8-хлор-1-метил-2,3,4,5-тетрагидро-1h-3-бензазепина
DK1761522T3 (da) Forbindelser og fremgangsmåder til behandling af dyslipidæmi
DE602004017703D1 (de) Phenyl- und pyridylpiperidinderivate als modulatoren des glucose-metabolismus
ATE530519T1 (de) Cyclobutylaminderivate
DK1644336T3 (da) Nitrogenholdige heteroarylforbindelser og deres anvendelse til forøgelse af endogent erythropoietin
NO20071438L (no) 4-arylspirosykloalky 1-2-aminopyrimidinkarboksamid KCNQ kaliumkanal modulerende forbindelser
NO20082116L (no) Kjemisk fremgangsmate for fremstilling av en amido-fenoksybenzosyreforbindelse
NO20081905L (no) Benzotiazolcyklobutylaminderivater og deres anvendelse som histamin-3-reseptorligander
MX2008013175A (es) Compuestos derivados de hidrazona de n-fenil-1,1,1-trifluorometasu lfonamida y su uso para controlar parasitos.
WO2004099197A3 (de) Substituierte oxyarene und deren verwendung zur bekämpfung von schädlingen
DE602004023529D1 (de) Regelung der Güte (Q) von Filtern
NZ719688A (en) Pesticidal compositions and related methods
DK1599455T3 (da) 4-(3-(2-phenyl-oxazol-4-ylmethoxy)-cyclohexyloxy)-butansyrederivater og beslægtede forbindelser som PPAR modulatorer til behandling af type 2 diabetes og aterosclerose
NO20050885D0 (no) Ny fremgangsmate for syntesen av 1,3-dihydro-2H-3-benzazepin-2-onforbindelser, og anvendelse i syntesen av ivabradin og addisjonssalter derav med en farmasoytisk akseptabel syre
MA25664A1 (fr) Nouveau cristal stable de derive de thiazolidinedione et procede de sa fabrication.
DE60311284D1 (de) 4-(3,5-dicyanophenoxy)pyrazol-derivate zur verwendung als reverse transkriptase modulatoren zur behandlung von u.a. hiv
WO2006021654A8 (fr) Derives de 4-arylmorpholin-3-one, leur preparation et leur application en therapeutique
PL373929A1 (pl) Sposób wytwarzania N-(5-amino-2-metylofenylo)-4-(3-pirydylo)-2-pirydynoaminy
EP1486497A4 (en) NEW PYRIDONE DERIVATIVE
WO2006031764A3 (en) Processes for prepating n-(substituted arylmethyl)-4-(disubstituted methyl)piperidines and intermediates
ATE397603T1 (de) Herstellungsverfahren von kristallinem losartan- kaliumsalz